Loading...
•
Dec 31, 2024
Quanterix Q4 2024 Earnings Report
Quanterix reported its seventh consecutive quarter of double-digit revenue growth in Q4 2024.
Key Takeaways
Quanterix achieved 11% year-over-year revenue growth in Q4 2024, reaching $35.2 million. However, net loss widened to $11.6 million, driven by increased operating expenses. The company continues to expand into immunology and oncology markets while advancing its planned acquisition of Akoya Biosciences. Adjusted gross margin improved to 57.7% from 54.7% in the prior year, reflecting stronger operational efficiency.
Revenue increased by 11% year-over-year to $35.2 million.
Net loss widened to $11.6 million, compared to $8.8 million in Q4 2023.
Adjusted gross margin improved to 57.7%, up from 54.7% in the prior year.
The company continues its strategic expansion into immunology and oncology markets.
Quanterix
Quanterix
Forward Guidance
Quanterix expects moderate revenue growth in 2025 while focusing on efficiency improvements and completing the Akoya acquisition.
Positive Outlook
- Projected 2025 revenue growth of 2% to 6%, reaching up to $146 million.
- Expansion into immunology and oncology broadening the addressable market.
- Adjusted gross margin expected to remain strong between 53% and 57%.
- Strategic acquisition of Akoya Biosciences to enhance biomarker detection capabilities.
- Launch of the Simoa ONE platform expected to drive future product adoption.
Challenges Ahead
- Net loss continues to expand due to higher operating expenses.
- Integration risks associated with the pending Akoya Biosciences acquisition.
- Increased cash usage projected at $55 million to $65 million in 2025.
- Capital-constrained environment may impact sales growth in key markets.
- Regulatory and market uncertainties surrounding new product launches.